Inhaling High-Dose CO2 Could Clear Alzheimer’s Proteins, Study Shows

Researchers at the University of New Mexico presented evidence this week that inhaling high-dose carbon dioxide for half an hour flushes amyloid and tau proteins linked to Alzheimer’s disease from the brain. The gas causes blood vessels to constrict and dilate while people are awake, mimicking the brain activity that occurs during deep sleep. This pumping action turbocharges the glymphatic system, the brain’s waste-disposal network, to clear harmful protein buildup. The study involved a small group with no reported side effects, but long-term safety remains unknown.

How the CO2 treatment works

The brain’s glymphatic system removes waste products through channels surrounding blood vessels. It operates most actively during deep sleep, when slow brain waves cause blood vessels to dilate and constrict roughly once every 30 seconds. Inhaling high-dose CO2 mimics this pumping action while people are awake, according to researcher Sephira Ryman at the University of New Mexico. The dilation and constriction essentially serves as a pump that clears waste from the brain.

Study results and safety concerns

None of the study participants experienced side effects from the 30-minute CO2 exposure. However, Ryman stressed that long-term safety data is still needed. People should not attempt to inhale carbon dioxide at home, she warned. In research settings, participants receive carefully controlled concentrations under continuous medical supervision with specialised equipment monitoring safety throughout the procedure. Breathing higher concentrations outside controlled settings can be dangerous and life-threatening.

Broader implications for neurodegenerative disease

A 2025 study suggests the same CO2 approach could help clear alpha-synuclein protein in Parkinson’s disease. Ryman noted that any condition caused by or worsened by waste accumulation could potentially benefit from this treatment. The findings were presented at the Alzheimer’s Association International Conference in London last week, where researchers are exploring multiple treatment targets for Alzheimer’s disease. The field is moving toward therapies aimed at different disease pathways rather than a one-size-fits-all approach.

Next steps in research and treatment

Clinical trials will be needed to validate the CO2 treatment and establish safe protocols for broader use. Researchers are also investigating whether Alzheimer’s disease comprises multiple subtypes driven by different biological factors, which could explain why some therapies fail in trials. Understanding these subtypes may help match patients to the most effective treatments. The discovery adds to recent progress in Alzheimer’s care, including the first disease-modifying therapies and blood-based biomarker tests that can now identify the disease earlier.

Final Thoughts

The CO2 inhalation study offers a potential new tool for clearing Alzheimer’s proteins from the brain, but rigorous trials and long-term safety data are essential before clinical use. Patients should await medical guidance rather than attempting home treatment.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.